CJC-1295 / Ipamorelin vs Tesamorelin / Ipamorelin
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two seller blends built on the same idea, a GHRH copy plus a ghrelin copy. The difference is that one of the GHRH halves is an FDA approved drug with large final stage trial data, and the other is not approved anywhere. Neither pair has been studied.
- CJC-1295 / Ipamorelin people
- 20
- CJC-1295 / Ipamorelin nulls
- 0
- Tesamorelin / Ipamorelin people
- 1,507
- Tesamorelin / Ipamorelin nulls
- 1
Dose
No human dose established for this blend
No published study has tested CJC-1295 with ipamorelin together. Each component has its own profile. Commonly reported chips track the CJC-1295 half of the vial and are not a human dose.
Amounts for the CJC-1295 in the blend, in mcg, commonly reported. The ipamorelin moves with it in the label ratio.
Amounts commonly reported for the CJC-1295 in this blend, recorded for this archive's reconstitution calculator, are 100, 200 and 300 mcg. They are self-reports rather than trial doses, and this archive does not recommend any of them. No human dose has been established for CJC-1295 / Ipamorelin.
| Reported amount | Where the number comes from |
|---|---|
| 100 mcg | Commonly reported, no published human dosing trial |
| 200 mcg | Commonly reported, no published human dosing trial |
| 300 mcg | Commonly reported, no published human dosing trial |
Dose
Approved label amounts
1 and 2 mg
Amounts for the tesamorelin in the blend, in mg. 2 mg is the approved tesamorelin label; the ipamorelin moves with it in the label ratio.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
CJC-1295 / IpamorelinCJC-1295 and Ipamorelin blend (GHRH analogue plus ghrelin mimetic)
The most popular peptide pair on the market. It is sold as 5 mg plus 5 mg, or 10 mg plus 10 mg, in one vial, so each peptide is half the powder by weight. No published study has tested CJC-1295 with ipamorelin in people or in animals. And the two peptides clear from the body at speeds roughly a hundredfold apart, so no single shot schedule is right for both.
Column B
Tesamorelin / IpamorelinTesamorelin and Ipamorelin blend (approved GHRH analogue plus ghrelin mimetic)
The clinic version of the growth hormone blend. It pairs tesamorelin, a GHRH copy with FDA approval and results from 806 patients in large final-stage trials, with ipamorelin, whose one human trial missed its goal. No study has tested the two together. On the common 5 mg plus 5 mg vial, getting the 2 mg tesamorelin dose behind the approved result also gives you 2 mg of ipamorelin. That is roughly seven to ten times the dose ipamorelin is used at alone.
Side by side, on the facts we can check
| What we compare | CJC-1295 / Ipamorelin | Tesamorelin / Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not approved. Neither part is an approved drug, and the mix has never been sent to a regulator or studied. | Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta, for the shifted body fat some people with HIV get. Ipamorelin is not approved, and no combination product exists. |
| Half-life | Not one number. The two components clear on completely different timescales, one within a few hours and the other over about a week. | Not one number. Both components clear within hours, but not at the same rate, and neither has been measured in the presence of the other. |
| Molecular weight | Mixture; CJC-1295 with DAC about 3,647.2 Da, ipamorelin 711.85 Da | Mixture; tesamorelin 5,135.9 Da, ipamorelin 711.85 Da |
| How it works | Two switches on the same pituitary cell. CJC-1295 presses the GHRH switch, which makes each growth hormone burst bigger. In the DAC version, a hook that grabs albumin, a blood protein, stretches that signal out for days. Ipamorelin presses the ghrelin switch, called GHS-R1a. That releases growth hormone and also eases off somatostatin, the body's brake on growth hormone. In human tests, pressing both kinds of switch gave a bigger burst than either alone. But those tests used the body's own GHRH with GHRP-6, not this pair. | Tesamorelin presses the GHRH switch in the pituitary. That makes the body's own growth hormone bursts bigger, while the brain's feedback checks stay in place. That is what let it cut deep belly fat without the effects of giving growth hormone directly. Ipamorelin presses the ghrelin switch, GHS-R1a, on the same cell. That is a separate route that also releases growth hormone and eases off somatostatin, the body's brake on growth hormone. The idea is that two different switches give a bigger burst than either alone. That holds for GHRH plus GHRP-type peptides in one-time human tests. It has not been tested for this pair. |
| Studies in people | 3 | 5 |
| Evidence | Limited: 2 completed trials, 20 people given it | Strong: 5 completed trials, 1,507 people given it |
| Legal status, US | Not approved; research use only | No approved blend; tesamorelin alone is approved as Egrifta |
Frequently asked questions
What is the difference between CJC-1295 / Ipamorelin and Tesamorelin / Ipamorelin?
CJC-1295 / Ipamorelin: The most popular peptide pair on the market. It is sold as 5 mg plus 5 mg, or 10 mg plus 10 mg, in one vial, so each peptide is half the powder by weight. No published study has tested CJC-1295 with ipamorelin in people or in animals. And the two peptides clear from the body at speeds roughly a hundredfold apart, so no single shot schedule is right for both. Tesamorelin / Ipamorelin: The clinic version of the growth hormone blend. It pairs tesamorelin, a GHRH copy with FDA approval and results from 806 patients in large final-stage trials, with ipamorelin, whose one human trial missed its goal. No study has tested the two together. On the common 5 mg plus 5 mg vial, getting the 2 mg tesamorelin dose behind the approved result also gives you 2 mg of ipamorelin. That is roughly seven to ten times the dose ipamorelin is used at alone.
Which has stronger research evidence, CJC-1295 / Ipamorelin or Tesamorelin / Ipamorelin?
Each compound gets a band worked out from facts we counted, with the math shown. CJC-1295 / Ipamorelin is Limited (2 completed trials, 20 people given it). Tesamorelin / Ipamorelin is Strong (5 completed trials, 1,507 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are CJC-1295 / Ipamorelin and Tesamorelin / Ipamorelin FDA-approved?
CJC-1295 / Ipamorelin: Not approved. Neither part is an approved drug, and the mix has never been sent to a regulator or studied.. Tesamorelin / Ipamorelin: Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta, for the shifted body fat some people with HIV get. Ipamorelin is not approved, and no combination product exists..
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.